A Combination of an Antimitotic and a Bromodomain 4 Inhibitor Synergistically Inhibits the Metastatic MDA-MB-231 Breast Cancer Cell Line

Figure 7

Caspase 6 activity ratios of vehicle-treated, ESE-15-ol-treated, ITH-47-treated, and combination-treated MDA-MB-231 (a) and MCF-7 (b) cells after 48 hours of exposure. Activity of caspase 6 was increased in the combination-treated MDA-MB-231 cells when compared to the vehicle-treated cells. indicates a value <0.05 whereas indicates value <0.01.

(a)

(b)